You can buy or sell CLVS and other stocks, options, ETFs, and crypto commission-free!
Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Read More Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. The listed name for CLVS is Clovis Oncology, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 5, After Hours